Steve Pakola - 01 Jan 2022 Form 4 Insider Report for REGENXBIO Inc. (RGNX)

Role: Chief Medical Officer
Signature: /s/ Patrick J. Christmas as attorney-in-fact
Issuer symbol: RGNX
Transactions as of: 01 Jan 2022
Net transactions value: -$91,603
Form type: 4
Filing time: 04 Jan 2022, 20:05:30 UTC
Next filing: 05 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RGNX	Common Stock	Tax liability	$37,670	-1,152	-10%	$32.70	9,848	01 Jan 2022	Direct
transaction	RGNX	Common Stock	Sale	$53,932	-1,598	-16%	$33.75	8,250	03 Jan 2022	Direct	F1, F2
transaction	RGNX	Common Stock	Award	$0	+8,900	+108%	$0.000000	17,150	03 Jan 2022	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RGNX	Stock Option (Right to Buy)	Award	$0	+42,500		$0.000000	42,500	03 Jan 2022	Common Stock	42,500	$34.31	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was effected pursuant to a Rule 10b5-1 trading plan.
F2	This transaction was executed in multiple trades at prices ranging from $33.72 to $33.81. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3	Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026 while the recipient provides continuous service to the Issuer.
F4	25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 3, 2023 while the optionee provides continuous service to the Issuer.